Conggang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Conggang Zhang has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Xuxu Sun
Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
20 shared publications - Zhengyin Zhang
School of Pharmaceutical Sciences, State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University, Beijing, China
20 shared publications - Huili Su
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
19 shared publications - Jing Han
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
19 shared publications - Peng Liu
School of Biomedical Engineering, Tsinghua Medicine, Tsinghua University, Beijing, China
19 shared publications - Shuiqing Hu
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas
19 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (7) , 117576
VEGFR2 inhibition potentiates STING-mediated antitumor immunity
- 18 June 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (7) , 117576
Open AccessVEGFR2 inhibition potentiates STING-mediated antitumor immunity
- Open Access
Pro-IL-1β activates NF-κB independently of maturation
Interleukin-1β (IL-1β) is an essential pro-inflammatory cytokine which functions as a key factor in innate immunity. The precursor protein, pro-IL-1β, has long been regarded as an inactive form in innate immune responses. Here, we unveil the biological function and regulation of pro-IL-1β in activating the NF-κB signaling pathway, which is distinct from IL-1β signaling. The expression and release of pro-IL-1β are induced by inflammatory stimuli and then pro-IL-1β acutely activates the gene transcription driven by NF-κB in a dose dependent manner. This activity is resistant to IL-1 receptor antagonist (IL-1Ra). The signal transduction triggered by pro-IL-1β relies on MyD88 and endocytosis. We further demonstrate that the N-terminal pro-peptide primarily contributes to this activity. Furthermore, we identify TLR7 and TLR8 as the binding partners of pro-IL-1β in vitro and as the potential receptors mediating pro-IL-1β-induced NF-κB activation. Collectively, this study sheds light on the unique cytokine function of pro-IL-1β and provides new insights into the functional characterization of pro-cytokines in innate immunity.
Open AccessPro-IL-1β activates NF-κB independently of maturation
Interleukin-1β (IL-1β) is an essential pro-inflammatory cytokine which functions as a key factor in innate immunity. The precursor protein, pro-IL-1β, has long been regarded as an inactive form in innate immune responses. Here, we unveil the biological function and regulation of pro-IL-1β in activating the NF-κB signaling pathway, which is distinct from IL-1β signaling. The expression and release of pro-IL-1β are induced by inflammatory stimuli and then pro-IL-1β acutely activates the gene transcription driven by NF-κB in a dose dependent manner. This activity is resistant to IL-1 receptor antagonist (IL-1Ra). The signal transduction triggered by pro-IL-1β relies on MyD88 and endocytosis. We further demonstrate that the N-terminal pro-peptide primarily contributes to this activity. Furthermore, we identify TLR7 and TLR8 as the binding partners of pro-IL-1β in vitro and as the potential receptors mediating pro-IL-1β-induced NF-κB activation. Collectively, this study sheds light on the unique cytokine function of pro-IL-1β and provides new insights into the functional characterization of pro-cytokines in innate immunity.
- Open Access
- 10 December 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (2) , 111038
Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity
- 10 December 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (2) , 111038
Open AccessActivation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Movie from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Figures S1 to S9 with Legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Supplementary Figures S1 to S9 with Legends
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I IFNs and other cytokines. Pharmacologic activation of STING is considered a potent therapeutic strategy in cancer. In this study, we used a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity
Cyclic GMP–AMP (cGAMP) is a second messenger that activates the stimulator of interferon genes (STING) innate immune pathway to induce the expression of type I IFNs and other cytokines. Pharmacologic activation of STING is considered a potent therapeutic strategy in cancer. In this study, we used a cell-based phenotypic screen and identified podophyllotoxin (podofilox), a microtubule destabilizer, as a robust enhancer of the cGAMP–STING signaling pathway. We found that podofilox enhanced the cGAMP-mediated immune response by increasing STING-containing membrane puncta and the extent of STING oligomerization. Furthermore, podofilox changed the trafficking pattern of STING and delayed trafficking-mediated STING degradation. Importantly, the combination of cGAMP and podofilox had profound antitumor effects on mice by activating the immune response through host STING signaling. Together, these data provide insights into the regulation of cGAMP–STING pathway activation and demonstrate what we believe to be a novel approach for modulating this pathway and thereby promoting antitumor immunity.
- Open Access
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway is a central regulator of innate immunity and a promising target for cancer immunotherapy. However, the clinical translation of STING agonists is limited by suboptimal response rates and dose-limiting toxicities, particularly in the liver. These challenges highlight the presence of endogenous inhibitors of STING signaling and underscore the need for strategies that enable tissue-specific modulation of STING activity. Here, we identify proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol metabolism, as a negative modulator of STING activation. Mechanistically, PCSK9 competes with STING for binding to a shared cargo receptor, which is critical for STING trafficking. PCSK9 deficiency markedly enhances the immunostimulatory effects of STING agonists. Capitalizing on the elevated expression of PCSK9 in the liver relative to tumors, we develop a formulation that delivers a low-dose STING agonist alongside PCSK9-targeting siRNA, thereby achieving tumor-selective STING activation while minimizing hepatotoxicity. These findings reveal an unanticipated role for PCSK9 in innate immune regulation and establish a therapeutic approach to enhance the safety and efficacy of STING-based immunotherapies, with broader implications for other STING-associated modalities, including radiotherapy and chemotherapy.
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessSilencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway is a central regulator of innate immunity and a promising target for cancer immunotherapy. However, the clinical translation of STING agonists is limited by suboptimal response rates and dose-limiting toxicities, particularly in the liver. These challenges highlight the presence of endogenous inhibitors of STING signaling and underscore the need for strategies that enable tissue-specific modulation of STING activity. Here, we identify proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol metabolism, as a negative modulator of STING activation. Mechanistically, PCSK9 competes with STING for binding to a shared cargo receptor, which is critical for STING trafficking. PCSK9 deficiency markedly enhances the immunostimulatory effects of STING agonists. Capitalizing on the elevated expression of PCSK9 in the liver relative to tumors, we develop a formulation that delivers a low-dose STING agonist alongside PCSK9-targeting siRNA, thereby achieving tumor-selective STING activation while minimizing hepatotoxicity. These findings reveal an unanticipated role for PCSK9 in innate immune regulation and establish a therapeutic approach to enhance the safety and efficacy of STING-based immunotherapies, with broader implications for other STING-associated modalities, including radiotherapy and chemotherapy.
- Top Cited Papers
- 7 January 2025
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 25 (6) , 425-444
Regulation of cGAS–STING signalling and its diversity of cellular outcomes
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signalling pathway, which recognizes both pathogen DNA and host-derived DNA, has emerged as a crucial component of the innate immune system, having important roles in antimicrobial defence, inflammatory disease, ageing, autoimmunity and cancer. Recent work suggests that the regulation of cGAS–STING signalling is complex and sophisticated. In this Review, we describe recent insights from structural studies that have helped to elucidate the molecular mechanisms of the cGAS–STING signalling cascade and we discuss how the cGAS–STING pathway is regulated by both activating and inhibitory factors. Furthermore, we summarize the newly emerging understanding of crosstalk between cGAS–STING signalling and other signalling pathways and provide examples to highlight the wide variety of cellular processes in which cGAS–STING signalling is involved, including autophagy, metabolism, ageing, inflammation and tumorigenesis.
- 7 January 2025
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 25 (6) , 425-444
Top Cited PapersRegulation of cGAS–STING signalling and its diversity of cellular outcomes
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signalling pathway, which recognizes both pathogen DNA and host-derived DNA, has emerged as a crucial component of the innate immune system, having important roles in antimicrobial defence, inflammatory disease, ageing, autoimmunity and cancer. Recent work suggests that the regulation of cGAS–STING signalling is complex and sophisticated. In this Review, we describe recent insights from structural studies that have helped to elucidate the molecular mechanisms of the cGAS–STING signalling cascade and we discuss how the cGAS–STING pathway is regulated by both activating and inhibitory factors. Furthermore, we summarize the newly emerging understanding of crosstalk between cGAS–STING signalling and other signalling pathways and provide examples to highlight the wide variety of cellular processes in which cGAS–STING signalling is involved, including autophagy, metabolism, ageing, inflammation and tumorigenesis.